Live feed08:30:00·254dPRReleasevia QuantisnowMural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per ShareByQuantisnow·Wall Street's wire, on your screen.MURA· Mural Oncology plcXOMA· XOMA Royalty CorporationHealth Care
